Allergo Journal International最新文献

{"title":"What should be considered during epicutaneous patch testing?","authors":"Richard Brans,&nbsp; Vera Mahler","doi":"10.1007/s40629-023-00243-y","DOIUrl":"10.1007/s40629-023-00243-y","url":null,"abstract":"<div><p>Indications for epicutaneous patch testing include the detection or exclusion of allergic contact dermatitis of the skin, transitional mucosa or oral mucosa, suspected delayed-type immune reactions to ingredients of implants, and certain drug reactions (maculopapular exanthema, symmetrical drug-related intertriginous and flexural exanthema [SDRIFE], acute generalized exanthematous pustulosis [AGEP], and fixed drug eruption). When available, allergen preparations that have been pharmaceutically tested and that are approved or marketable as medicinal products should be used. Existing diagnostic gaps can be closed by testing the patient’s own materials in a suitable preparation. Interferences of ultraviolet (UV) light exposure or drugs with patch test reactions have to be considered. In addition to the reading after 48 h and 72 h, a further reading between day 7 (168 h) and day 10 (240 h) is useful, since about 15% of the positive test reactions remain undetected without this late reading. All positive patch test reactions considered allergic must be evaluated with regard to their clinical relevance based on existing exposures.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"32 3","pages":"77 - 82"},"PeriodicalIF":0.0,"publicationDate":"2023-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-023-00243-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42775324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patients with asthma consulting an allergist differ from those consulting a pulmonologist","authors":"Giorgio Ciprandi MD,&nbsp;Irene Schiavetti PhD,&nbsp;Fabio Luigi Massimo Ricciardolo PhD","doi":"10.1007/s40629-023-00244-x","DOIUrl":"10.1007/s40629-023-00244-x","url":null,"abstract":"","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"32 5","pages":"154 - 155"},"PeriodicalIF":0.0,"publicationDate":"2023-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47640285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronavirus infection in an unvaccinated atopic dermatitis patient under ongoing dupilumab therapy: eczema flare-up, but moderate COVID-19 symptoms","authors":"Natalie Anasiewicz MD,&nbsp;Corsin Seeli MD,&nbsp;Marie-Charlotte Brüggen MD, PhD,&nbsp; Matthias Möhrenschlager MD","doi":"10.1007/s40629-023-00245-w","DOIUrl":"10.1007/s40629-023-00245-w","url":null,"abstract":"","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"32 6","pages":"176 - 177"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-023-00245-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9237392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allergen immunotherapy in house dust mite-associated allergic rhinitis: efficacy of the 300 IR mite tablet","authors":"Ludger Klimek,&nbsp;Randolf Brehler,&nbsp;Ingrid Casper,&nbsp;Felix Klimek,&nbsp;Jan Hagemann,&nbsp;Mandy Cuevas,&nbsp; Karl-Christian Bergmann","doi":"10.1007/s40629-022-00241-6","DOIUrl":"10.1007/s40629-022-00241-6","url":null,"abstract":"<div><h3>Background</h3><p>A perennial house dust mite-associated allergic rhinitis has a major impact on the quality of life of patients and is associated with a high socioeconomic burden. The most common symptoms of allergic rhinitis include a runny nose and nasal congestion, sneezing, itching of nose, mouth and/or throat, and/or ocular symptoms. Affected patients often develop allergic bronchial asthma. Therapy options for allergic rhinitis include allergen avoidance, symptomatic treatment, and allergen immunotherapy. Allergen immunotherapy is the only disease-modifying treatment that can permanently alleviate the symptoms of allergic rhinitis. In July 2021, a new sublingual mite tablet was approved in Germany.</p><h3>Methods</h3><p>This review summarizes clinical studies on the 300 IR (index of reactivity) mite tablet in adolescents and adults with house dust mite-associated allergic rhinitis and presents the results.</p><h3>Results</h3><p>In the phase II and phase III studies considered here, different dosages of the mite tablet were investigated. The 300 IR mite tablet showed the best benefit–risk profile and has been approved in Europe, Japan, South Korea, Australia, and New Zealand for the treatment of house dust mite-associated allergic rhinitis.</p><h3>Conclusion</h3><p> Allergen immunotherapy with the 300 IR mite tablet is an effective treatment that relieves allergic symptoms, reduces the need for symptomatic medication, and improves the quality of life in both adults and adolescents with house dust mite-associated allergic rhinitis. At the same time, treatment with the 300 IR mite tablet is well tolerated. Mild to moderate reactions at the application site subside after a few days.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"32 1","pages":"10 - 17"},"PeriodicalIF":0.0,"publicationDate":"2023-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00241-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43680325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High pan-allergen content in mango and peach in Taiwan","authors":"Mey Fann Lee PhD,&nbsp;Yi Hsing Chen MD, PhD,&nbsp;Yu-Wen Chu PhD,&nbsp;Ping Cheng Hsieh MS,&nbsp;Nancy M. Wang PhD","doi":"10.1007/s40629-022-00240-7","DOIUrl":"10.1007/s40629-022-00240-7","url":null,"abstract":"<div><h3>Background</h3><p>Many plant food allergens have been implicated in cross-reactivities and may cause repetitive pan-allergenic exposures, which increase the severity of patients’ allergic symptoms. Identification of allergenic protein levels in food allows for more precise dietary advice. This study aimed to determine LTP, profilin, and PR-10 in the 15 most popular fruits in Taiwan.</p><h3>Methods</h3><p>cDNA encoding profilin (Sola l 1), nonspecific lipid transfer protein (nsLTP, Sola l 3), and pathogenesis-related protein (PR-10, Sola l 4) were cloned into the pQE30, expressed in <i>Escherichia coli</i>, and purified. Extracts of the most popular fruits, including apple, banana, carrot, celery, dragon fruit, hami melon, jujube, kiwi, mango, melon, orange, papaya, peach, persimmon, and tomato, in Taiwan were prepared in PBS. The allergenic protein levels in these extracts were determined by immuno-dot blotting using rabbit anti-rSola l 1, 3, and 4 polyclonal antibodies.</p><h3>Results</h3><p>Among all 15 fruit extracts tested, peach and mango contained the highest levels of profilin, nsLTP, and PR-10. Papaya, melon, and tomato contained low but detectable levels of the three pan-allergens.</p><h3>Conclusion</h3><p>Our data suggest that peach and mango contain the highest levels of important pan-allergens among the 15 common fruits tested, which agrees with epidemiological data.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"32 4","pages":"97 - 103"},"PeriodicalIF":0.0,"publicationDate":"2023-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00240-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42080272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Avoidance measures for mite allergy—an update","authors":"Ludger Klimek,&nbsp;Randolf Brehler,&nbsp;Karl-Christian Bergmann,&nbsp;Ingrid Casper,&nbsp;Felix Klimek,&nbsp;Jan Hagemann,&nbsp;Marie-Luise Polk,&nbsp; Mandy Cuevas M.D.","doi":"10.1007/s40629-022-00242-5","DOIUrl":"10.1007/s40629-022-00242-5","url":null,"abstract":"<div><p>House dust mites are a major source of allergens in house dust and, thus, the main trigger of perennial allergic respiratory diseases [1,2,3,4,5]. Scientific research on the life cycle, diet, and reproductive behavior of dust mites and on the biology of mite allergens has uncovered mechanisms leading to the development of respiratory allergies and suggests measures that can minimize exposure to dust mite allergens. Here, we discuss the evidence linking house dust mite exposure and respiratory allergies and present the efficacy of avoidance measures and their scientific evidence.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"32 1","pages":"18 - 27"},"PeriodicalIF":0.0,"publicationDate":"2023-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00242-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42036595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validity of anamnestic data on allergies towards β-lactam antibiotics in a preoperative setting","authors":"Katharina Luwich,&nbsp;Eva Lücke,&nbsp;Thomas Hachenberg,&nbsp;Sabine Stegemann-Koniszewski,&nbsp;Robin John,&nbsp;Rüdiger Braun-Dullaeus,&nbsp;Jens Schreiber","doi":"10.1007/s40629-022-00238-1","DOIUrl":"10.1007/s40629-022-00238-1","url":null,"abstract":"","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"32 4","pages":"114 - 116"},"PeriodicalIF":0.0,"publicationDate":"2023-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00238-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44485484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety in switching Hymenoptera venom immunotherapy manufacturers","authors":"Mariana Bragança MD,&nbsp;Daniela Brandão Abreu MD,&nbsp;Luís Amaral MD,&nbsp;José Luís Plácido MD,&nbsp;Alice Coimbra MD","doi":"10.1007/s40629-022-00237-2","DOIUrl":"10.1007/s40629-022-00237-2","url":null,"abstract":"","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"32 3","pages":"95 - 96"},"PeriodicalIF":0.0,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00237-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48194017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of medications for antihistamine-refractory chronic spontaneous urticaria: a systematic review and network meta-analysis","authors":"Benjamin Kendziora M.D. Ph.D.,&nbsp;Jessica Frey,&nbsp; Markus Reinholz M.D. Ph.D.,&nbsp; Franziska Ruëff M.D.,&nbsp;Eva Oppel M.D.,&nbsp; Torsten Zuberbier M.D.,&nbsp; Daniela Hartmann M.D. Ph.D.,&nbsp;Justin G. Schlager M.D.,&nbsp; Lars E. French M.D.","doi":"10.1007/s40629-022-00235-4","DOIUrl":"10.1007/s40629-022-00235-4","url":null,"abstract":"<div><h2>Summary</h2><div><h3>Purpose</h3><p>Most medications for antihistamine-refractory chronic spontaneous urticaria (CSU) have not been compared head-to-head. This systematic review and network meta-analysis evaluates their relative efficacy and safety.</p><h3>Methods</h3><p>Electronic databases were searched until 05 May 2022 for randomized controlled trials investigating systemic medications for antihistamine-refractory CSU. The change in the urticaria activity score over seven days (UAS7) and occurrence of adverse events were compared between treatments using random-effects network meta-analysis models.</p><h3>Results</h3><p>In all, 32 studies with 3641 patients receiving 31 different systemic medical interventions were included. Among currently available drugs, omalizumab 300 mg injected every 4 weeks and cyclosporine 3–5 mg/kg daily per os were most effective in reducing the UAS7 with a reduction of −10.45 (95% confidence interval [CI]: −12.35, −8.55) and of −10.40 (95% CI: −19.4, −1.4) compared to placebo. Similar efficacies were shown by the nonapproved agents ligelizumab 72 mg injected every 4 weeks (−11.67, 95% CI: −16.80, −7.15) and fenebrutinib 400 mg daily per os (−9.50, 95% CI: −17.56, −1.44). The odds ratio for the occurrence of an adverse event with placebo as comparator was 1.09 for omalizumab (95% CI: 0.83, 1.42), 2.16 for cyclosporine (95% CI: 0.77, 6.07: GRADE; moderate certainty), 0.89 for ligelizumab (95% CI: 0.47, 1.69), and 2.14 for fenebrutinib (95% CI: 0.62, 7.38) in the mentioned dosages.</p><h3>Conclusion</h3><p>Omalizumab 300 mg injected every 4 weeks and cyclosporine 3–5 mg/kg daily per os are the most effective currently available drugs for antihistamine-refractory CSU. Cyclosporine shows a relatively less favorable safety profile.</p></div></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"32 3","pages":"83 - 92"},"PeriodicalIF":0.0,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00235-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47243749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Papuloerythroderma of Ofuji (PEO) successfully treated with acitretin","authors":"Gabriela Blanchard MD, PhD,&nbsp; Emmanuella Guenova MD, PhD","doi":"10.1007/s40629-022-00236-3","DOIUrl":"10.1007/s40629-022-00236-3","url":null,"abstract":"","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"32 5","pages":"151 - 153"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00236-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41355896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}